Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Phase 2 Terminated 58 enrolled Huazhong University of Science and Technology

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Timeline

Start: 2020-04-03
Primary completion: 2023-11-30
Completion: 2023-11-30

Outcome

Met primary endpoint

Stopped (Enrollment): “slow recruitment forcing early suspension of screening and enrollment”

paper the Cam-NP group achieved a significantly higher ORR (33.3% vs. 10.7%; P = .039) PMID 40554667 ↗

Publications

Sun L, Gong Z, Wang L, Kuang L, Huang Q, Pei B, Yuan X, Qiu H. Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer. Oncologist. 2025 Jul 4;30(7):oyaf189. doi: 10.1093/oncolo/oyaf189.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Comparator	Nab-paclitaxel	Small molecule	100 mg/m2	Intravenous
Comparator	Nab-paclitaxel	Small molecule	125 mg/m2	Intravenous
Comparator	Nab-paclitaxel	Small molecule	130 mg/m2	Intravenous
Comparator	Nab-paclitaxel	Small molecule	260 mg/m2	Intravenous